Online citations, reference lists, and bibliographies.
← Back to Search

Critical Analysis Of Cancer Therapy Using Nanomaterials

L. Juillerat-Jeanneret
Published 2007 · Medicine

Cite This
Download PDF
Analyze on Scholarcy
Share
The sections in this article are Introduction Anticancer Therapies Characteristics of Nanoparticles for Cancer Therapy Nanovectors Biological Issues Nanoparticle Targeting: Passive or Active Nanovectors in Biomedical Applications: Drug Delivery Systems (DDS) for Cancer Physicochemical Drug Delivery Biological Drug Delivery Chemical Drug Delivery Nanoparticles for Anticancer Drug Delivery Existing Systems Systems under Development and Challenges Nanoparticles for Drug Delivery in Clinical Use or under Clinical Evaluation Doxorubicin Family Paclitaxel (Taxol) 5-Fluorouracil Tamoxifen Cisplatin Campthotecins Methotrexate New Experimental Drugs and Therapies Proteins, Peptides, their Inhibitors and Antagonists New Drugs New Therapeutic Approaches: Photodynamic Therapy (PDT) Gene Therapy Nanoparticle for Gene Delivery: Non-chitosan and Chitosan-type Polymers New Approaches Improvement of Biological Characteristics New Technological Approaches Superparamagnetic Iron Oxide Nanoparticles (SPIONs) as Magnetic Drug Nanovectors Targeting Passive Targeting Active Targeting Targeting Cancer-associated Cells Targeting Cancer Markers Intracellular Drug Delivery Development of the Necessary Chemistry: Synthetic Routes and Linkers for Conjugation Overcoming the Mechanisms of Resistance to Therapy of Cancers Toxicity Issues Conclusions Opportunities and Challenges of Nanomedicine in Cancer
This paper references
10.1021/MP034002C
Sustained cytoplasmic delivery of drugs with intracellular receptors using biodegradable nanoparticles.
J. Panyam (2004)
10.1517/14712598.4.8.1213
Nanoparticle-mediated gene delivery: state of the art
M. Ravi Kumar (2004)
10.1016/J.IJPHARM.2004.02.014
A novel in situ gel for sustained drug delivery and targeting.
S. Ganguly (2004)
10.3748/WJG.V10.I13.1989
Enhanced antitumor efficacy on hepatoma-bearing rats with adriamycin-loaded nanoparticles administered into hepatic artery.
Jiang-hao Chen (2004)
10.1016/S0168-3659(01)00341-8
Development of the polymer micelle carrier system for doxorubicin.
T. Nakanishi (2001)
10.1053/J.SEMINONCOL.2004.08.009
Future directions of liposome- and immunoliposome-based cancer therapeutics.
J. Park (2004)
10.1038/bjc.1996.587
Anthracycline antibiotics non-covalently incorporated into the block copolymer micelles: in vivo evaluation of anti-cancer activity.
E. Batrakova (1996)
10.1016/S0167-7799(97)01036-6
Biomedical applications of nanotechnology--implications for drug targeting and gene therapy.
S. Davis (1997)
10.1074/JBC.M301726200
Antennapedia and HIV Transactivator of Transcription (TAT) “Protein Transduction Domains” Promote Endocytosis of High Molecular Weight Cargo upon Binding to Cell Surface Glycosaminoglycans*
S. Console (2003)
10.1016/S0168-3659(03)00359-6
Agglomerated vesicle technology: a new class of particles for controlled and modulated pulmonary drug delivery.
R. Bhavane (2003)
10.1016/J.TET.2003.10.091
A new strategy for synthesis of polymeric supports with triazene linkers
R. Lazny (2004)
10.1006/JSRE.2000.6030
Clinical applications of magnetic drug targeting.
A. Lübbe (2001)
10.1166/JNN.2003.077
Influence of the surface properties on nanoparticle-mediated transport of drugs to the brain.
J. Kreuter (2004)
10.1089/CBR.2005.20.141
Calcium phosphate nanoparticles as a novel nonviral vector for efficient transfection of DNA in cancer gene therapy.
T. Liu (2005)
10.1080/1061186021000054933
Lymphatic Uptake of Pulmonary Delivered Radiolabelled Solid Lipid Nanoparticles
M. Videira (2002)
10.1021/BC00032A011
Heterobifunctional poly(ethylene oxide): synthesis of alpha-methoxy-omega-amino and alpha-hydroxy-omega-amino PEOs with the same molecular weights.
S. Cammas (1995)
10.1021/LA0478043
Oxidation-sensitive polymeric nanoparticles.
A. Rehor (2005)
10.1562/2004-05-24-RA-176.1
Photodynamic Characterization and In Vitro Application of Methylene Blue-containing Nanoparticle Platforms¶
Wei Tang (2005)
10.1016/S0168-3659(03)00211-6
An essential relationship between ATP depletion and chemosensitizing activity of Pluronic block copolymers.
A. Kabanov (2003)
10.1200/JCO.2005.00.802
Phase II study of a liposome-entrapped cisplatin analog (L-NDDP) administered intrapleurally and pathologic response rates in patients with malignant pleural mesothelioma.
C. Lu (2005)
10.1126/SCIENCE.1078192
Micellar Nanocontainers Distribute to Defined Cytoplasmic Organelles
R. Savić (2003)
10.1016/S0167-4889(02)00256-2
Therapeutic efficacy of anti-ErbB2 immunoliposomes targeted by a phage antibody selected for cellular endocytosis.
U. Nielsen (2002)
Effect of low-dose tumor necrosis factor-alpha in combination with STEALTH liposomal cisplatin (SPI-077) on soft-tissue- and osteosarcoma-bearing rats.
S. Hoving (2005)
10.1023/A:1013674200141
Poly(vinyl alcohol) hydrogels as hydrophilic matrices for the release of lipophilic drugs loaded in PLGA nanoparticles
Maria Grazia Cascone (2002)
10.1088/0031-9155/50/6/016
A biomagnetic system for in vivo cancer imaging.
E. Flynn (2005)
10.1016/S0168-3659(00)00269-8
Investigation of the role of macrophages on the cytotoxicity of doxorubicin and doxorubicin-loaded nanoparticles on M5076 cells in vitro.
C. E. Soma (2000)
10.1016/0014-5793(92)80655-Z
The polyoxyethylene/polyoxypropylene block co‐polymer Poloxamer‐407 selectively redirects intravenously injected microspheres to sinusoidal endothelial cells of rabbit bone marrow
C. Porter (1992)
10.1016/J.ADDR.2003.10.040
Polymeric anticancer drugs with pH-controlled activation.
K. Ulbrich (2004)
10.1021/JA0343095
Ceramic-based nanoparticles entrapping water-insoluble photosensitizing anticancer drugs: a novel drug-carrier system for photodynamic therapy.
I. Roy (2003)
10.1016/J.IJPHARM.2004.12.010
Poly(ethylene oxide)-modified poly(ɛ-caprolactone) nanoparticles for targeted delivery of tamoxifen in breast cancer
D. Shenoy (2005)
10.1016/S1359-6446(01)02088-8
Enzymatically cleavable linker groups in polymer-supported synthesis.
R. Reents (2002)
10.1016/S0939-6411(01)00175-8
Influence of the spacer on the inhibitory effect of different polycarbophil-protease inhibitor conjugates.
M. Marschütz (2001)
10.1006/MGME.2001.3223
Targeting tumor angiogenesis with gene therapy.
Q. Chen (2001)
10.1016/J.IJPHARM.2004.08.015
Uptake of folate-conjugated albumin nanoparticles to the SKOV3 cells.
L. Zhang (2004)
10.1002/cbic.200400174
Transport Of Surface‐Modified Nanoparticles Through Cell Monolayers
A. M. Koch (2005)
10.1096/fj.02-0088com
Rapid endo‐lysosomal escape of poly(DL‐lactide‐coglycolide) nanoparticles: implications for drug and gene delivery
J. Panyam (2002)
10.1023/A:1024963700223
Nanoparticle systems for the targeted release of active principles of proteic nature
R. Solaro (2003)
10.1016/S0168-3659(98)00124-2
Preliminary clinical study of the distribution of HPMA copolymers bearing doxorubicin and galactosamine.
P. Julyan (1999)
10.1038/nm1002
Targeting angiogenesis with a conjugate of HPMA copolymer and TNP-470
R. Satchi-Fainaro (2004)
10.1016/J.EJPB.2004.03.026
Cytotoxicity of anticancer drugs incorporated in solid lipid nanoparticles on HT-29 colorectal cancer cell line.
L. Serpe (2004)
10.1126/SCIENCE.303.5658.626
Cellular Distribution of Nonionic Micelles
S. M. Moghimi (2004)
10.1023/A:1018983904537
Significant Transport of Doxorubicin into the Brain with Polysorbate 80-Coated Nanoparticles
A. Gulyaev (2004)
10.1016/J.ADDR.2004.05.002
Micro and nano-fabrication of biodegradable polymers for drug delivery.
Y. Lu (2004)
10.2165/00003088-200342070-00005
Pharmacological Effects of Formulation Vehicles
A. J. Tije (2003)
10.1016/J.ADDR.2004.04.002
Configurational biomimesis in drug delivery: molecular imprinting of biologically significant molecules.
J. Z. Hilt (2004)
10.1016/S0168-3659(02)00320-6
A novel controlled release formulation for the anticancer drug paclitaxel (Taxol): PLGA nanoparticles containing vitamin E TPGS.
L. Mu (2003)
10.1002/JPS.2600690222
Tissue distribution of antitumor drugs associated with polyalkylcyanoacrylate nanoparticles.
P. Couvreur (1980)
10.1016/S0141-8130(99)00040-9
Synthetic poly(β-hydroxyalkanoates) with carboxylic acid or primary amine pendent groups and their complexes
H. Rossignol (1999)
10.1002/1520-6017(200011)89:11<1452::AID-JPS8>3.0.CO;2-P
Design of folic acid-conjugated nanoparticles for drug targeting.
B. Stella (2000)
10.1023/B:PHAM.0000003379.76417.3e
Uptake of Chitosan and Associated Insulin in Caco-2 Cell Monolayers: A Comparison Between Chitosan Molecules and Chitosan Nanoparticles
Zengshuan Ma (2004)
10.1038/nrd1775
Design and development of polymers for gene delivery
D. Pack (2005)
10.1126/SCIENCE.1095833
Drug Delivery Systems: Entering the Mainstream
T. Allen (2004)
10.1016/S0378-5173(00)00628-1
Tamoxifen encapsulation within polyethylene glycol-coated nanospheres. A new antiestrogen formulation.
I. Brigger (2001)
10.1021/BC00032A012
Formyl-ended heterobifunctional poly(ethylene oxide): synthesis of poly(ethylene oxide) with a formyl group at one end and a hydroxyl group at the other end.
Y. Nagasaki (1995)
10.1021/BI9618474
Design, synthesis, and characterization of a cationic peptide that binds to nucleic acids and permeabilizes bilayers.
T. B. Wyman (1997)
10.1016/J.JCIS.2004.09.042
Surface modification of monodisperse magnetite nanoparticles for improved intracellular uptake to breast cancer cells.
Y. Zhang (2005)
10.1016/J.JCONREL.2005.03.004
Preparation and characterization of intelligent core-shell nanoparticles based on poly(D,L-lactide)-g-poly(N-isopropyl acrylamide-co-methacrylic acid).
Chun-Liang Lo (2005)
10.1124/JPET.102.043307
Optimal Structure Requirements for Pluronic Block Copolymers in Modifying P-glycoprotein Drug Efflux Transporter Activity in Bovine Brain Microvessel Endothelial Cells
E. Batrakova (2003)
10.1016/0076-6879(93)21030-C
pH-sensitive liposomes for delivery of macromolecules into cytoplasm of cultured cells.
R. Straubinger (1993)
10.1016/S0378-5173(02)00336-8
Development of a polymeric nanoparticulate drug delivery system. In vitro characterization of nanoparticles based on sugar-containing conjugates.
I. Kim (2002)
10.1016/S0168-3659(99)00028-0
Preparation and characterization of polymer micelles from poly(ethylene glycol)-poly(D,L-lactide) block copolymers as potential drug carrier.
K. Yasugi (1999)
10.1038/nm996
Transducible TAT-HA fusogenic peptide enhances escape of TAT-fusion proteins after lipid raft macropinocytosis
J. Wadia (2004)
10.1097/01.rli.0000101027.57021.28
Macrophage Endocytosis of Superparamagnetic Iron Oxide Nanoparticles: Mechanisms and Comparison of Ferumoxides and Ferumoxtran-10
I. Raynal (2004)
10.4049/jimmunol.173.4.2578
pH-Triggered Microparticles for Peptide Vaccination1
W. Haining (2004)
10.1002/JPS.10556
Surface modification of poly(glycolic acid) (PGA) for biomedical applications.
Kyung-Bok Lee (2003)
10.1038/nbt875
The potential environmental impact of engineered nanomaterials
V. Colvin (2003)
10.1016/J.BIOMATERIALS.2004.07.023
Development of functionalized superparamagnetic iron oxide nanoparticles for interaction with human cancer cells.
A. Petri-Fink (2005)
10.1016/J.YEXCR.2004.07.021
Poly(lactide-co-glycolide) nanoparticles as a carrier system for delivering cysteine protease inhibitor cystatin into tumor cells.
Mateja Cegnar (2004)
10.1016/J.TETLET.2004.05.029
Dual linker with a reference cleavage site for information rich analysis of polymer-supported transformations
V. Krchňák (2004)
10.1016/J.JCONREL.2003.12.009
The effect of the linker on the hydrolysis rate of drug-linked ester bonds.
R. Schoenmakers (2004)
10.1248/CPB.44.1935
Preparation and characterization of poly(lactic-co-glycolic acid) microspheres for targeted delivery of a novel anticancer agent, taxol.
Y. Wang (1996)
10.1002/JPS.10507
Mechanistic study of the uptake of wheat germ agglutinin-conjugated PLGA nanoparticles by A549 cells.
Y. Mo (2004)
10.2460/AJVR.2004.65.1474
Preclinical evaluation of a liposome-encapsulated formulation of cisplatin in clinically normal dogs.
A. K. Marr (2004)
10.1038/sj.bjc.6601856
Phase I dose escalation and pharmacokinetic study of pluronic polymer-bound doxorubicin (SP1049C) in patients with advanced cancer
S. Danson (2004)
10.1126/SCIENCE.1070200
Tumor Regression by Targeted Gene Delivery to the Neovasculature
J. Hood (2002)
10.1038/nrc1566
Cancer nanotechnology: opportunities and challenges
M. Ferrari (2005)
10.1016/S0142-9612(01)00267-8
Surface modification of superparamagnetic magnetite nanoparticles and their intracellular uptake.
Y. Zhang (2002)
10.1038/nrd1088
The dawning era of polymer therapeutics
R. Duncan (2003)
10.1016/S0168-3659(01)00281-4
New HPMA copolymers containing doxorubicin bound via pH-sensitive linkage: synthesis and preliminary in vitro and in vivo biological properties.
T. Etrych (2001)
10.1021/MP0500014
Iron oxide nanoparticles for sustained delivery of anticancer agents.
Tapan Jain (2005)
10.1021/NL050127S
Immunotargeted nanoshells for integrated cancer imaging and therapy.
C. Loo (2005)
10.1016/S0168-3659(02)00212-2
Paclitaxel-loaded PLGA nanoparticles: preparation, physicochemical characterization and in vitro anti-tumoral activity.
Cristina Fonseca (2002)
10.1038/bjc.1997.362
Reversion of multidrug resistance with polyalkylcyanoacrylate nanoparticles: towards a mechanism of action.
A. C. de Verdière (1997)
10.1038/nrd1632
Recent advances with liposomes as pharmaceutical carriers
V. Torchilin (2005)
10.1016/S0168-3659(00)00302-3
Dextrans for targeted and sustained delivery of therapeutic and imaging agents.
R. Mehvar (2000)
10.1016/0378-5173(96)04559-0
Reversion of multidrug resistance using nanoparticles in vitro: Influence of the nature of the polymer
F. Nemati (1996)
10.1016/S0968-0896(99)00248-5
Syntheses and studies of multiwarhead siderophore-5-fluorouridine conjugates.
Y. Lu (1999)
10.1016/S1471-4914(02)00004-7
Nanoparticle-mediated gene delivery to tumour neovasculature.
A. Reynolds (2003)
10.1016/S0141-8130(99)00042-2
Polymers of malic acid and 3-alkylmalic acid as synthetic PHAs in the design of biocompatible hydrolyzable devices.
S. Cammas (1999)
10.1021/BM049234R
Formation of core/shell nanoparticles with a lipid core and their application as a drug delivery system.
K. S. Oh (2005)
10.1021/BM0300608
Investigation of the degradation mechanisms of poly(malic acid) esters in vitro and their related cytotoxicities on J774 macrophages.
Maria Elisa Martinez Barbosa (2004)
10.1615/CRITREVTHERDRUGCARRIERSYST.V18.I6.50
Complement activation-related pseudoallergy caused by liposomes, micellar carriers of intravenous drugs, and radiocontrast agents.
J. Szebeni (2001)
10.1016/0142-9612(90)90084-4
In vitro model for the degradation of alkylcyanoacrylate nanoparticles.
R. H. Müller (1990)
10.1016/S0163-7827(00)00011-4
Current status of pH-sensitive liposomes in drug delivery.
D. Drummond (2000)
10.1016/J.ADDR.2004.02.014
Nanoparticle and targeted systems for cancer therapy.
L. Brannon-Peppas (2004)
10.2174/0929867043455909
Nanoparticles of biodegradable polymers for clinical administration of paclitaxel.
S. Feng (2004)
10.1016/S0378-5173(03)00128-5
Development of polymeric nanoparticulate drug delivery systems: evaluation of nanoparticles based on biotinylated poly(ethylene glycol) with sugar moiety.
I. Kim (2003)
10.1016/S0168-3659(00)00364-3
Effects of emulsifiers on the controlled release of paclitaxel (Taxol) from nanospheres of biodegradable polymers.
S. Feng (2001)
10.1211/0022357055894
Tumour targeting: biological factors and formulation advances in injectable lipid nanoparticles
V. Shenoy (2005)
10.1021/BC025555T
Differential gene expression profile between PC-14 cells treated with free cisplatin and cisplatin-incorporated polymeric micelles.
N. Nishiyama (2003)
10.1158/0008-5472.CAN-04-3921
Nanoparticle targeting of anticancer drug improves therapeutic response in animal model of human epithelial cancer.
J. Kukowska-Latallo (2005)
10.1016/S0142-9612(99)00125-8
Reversion of multidrug resistance by co-encapsulation of doxorubicin and cyclosporin A in polyalkylcyanoacrylate nanoparticles.
C. E. Soma (2000)
10.1016/0014-2964(80)90053-5
Actinomycin D absorbed on polymethylcyanoacrylate nanoparticles: increased efficiency against an experimental tumor.
F. Brasseur (1980)
10.1163/1568562053654121
Poly(ethylene oxide)-b-poly(N-isopropylacrylamide) nanoparticles with cross-linked cores as drug carriers
Y. Zeng (2005)
10.1016/S0168-3659(01)00344-3
Adsorption and desorption of chemotherapeutic drugs from a magnetically targeted carrier (MTC).
S. Rudge (2001)
10.1002/ijc.10242
Intracellular targeting therapy of cisplatin‐encapsulated transferrin‐polyethylene glycol liposome on peritoneal dissemination of gastric cancer
H. Iinuma (2002)
10.1016/0006-2952(92)90443-M
Doxorubicin-loaded nanospheres bypass tumor cell multidrug resistance.
C. Cuvier (1992)
10.1016/S0378-5173(99)00012-5
Release of adriamycin from poly(γ-benzyl-l-glutamate)/poly(ethylene oxide) nanoparticles
In-Joon Oh (1999)
10.1096/fj.04-2747rev
Nanomedicine: current status and future prospects
S. Moghimi (2005)
10.1002/(SICI)1097-0215(19960611)66:6<821::AID-IJC19>3.0.CO;2-5
Photodynamic therapy of tumours with hexadecafluoro zinc phthalocyanine formulated in PEG‐coated poly(lactic acid) nanoparticles
E. Allémann (1996)
10.1038/nrd1494
Nanosuspensions in drug delivery
Barrett E. Rabinow (2004)
10.1016/j.jsbmb.2004.12.023
Innovative drug delivery nanosystems improve the anti-tumor activity in vitro and in vivo of anti-estrogens in human breast cancer and multiple myeloma
S. Maillard (2005)
10.1016/J.BIOMATERIALS.2004.10.012
Synthesis and surface engineering of iron oxide nanoparticles for biomedical applications.
A. Gupta (2005)
10.1038/sj.bjc.6602479
NK105, a paclitaxel-incorporating micellar nanoparticle formulation, can extend in vivo antitumour activity and reduce the neurotoxicity of paclitaxel
T. Hamaguchi (2005)
10.1016/S0040-4039(99)00160-4
Triazenes as robust and simple linkers for amines in solid-phase organic synthesis
S. Bräse (1999)
10.1016/S0040-4039(98)00593-0
A novel linker for the attachment of alcohols to solid supports
G. Böhm (1998)
10.1016/J.IJPHARM.2003.09.042
The influence of transferrin stabilised magnetic nanoparticles on human dermal fibroblasts in culture.
C. Berry (2004)
10.1016/S0168-3659(01)00263-2
N-isopropylacrylamide copolymers for the preparation of pH-sensitive liposomes and polymeric micelles.
J. Leroux (2001)
10.1016/J.JCONREL.2003.08.005
Drug delivery to resistant tumors: the potential of poly(alkyl cyanoacrylate) nanoparticles.
C. Vauthier (2003)
10.1002/JBM.820271214
The effect of phagocytosis of poly(L-lactic acid) fragments on cellular morphology and viability.
K. H. Lam (1993)
10.1016/S0163-7258(99)00018-2
Receptor-mediated and enzyme-dependent targeting of cytotoxic anticancer drugs.
G. Dubowchik (1999)
10.1163/1568562042368112
Formulation of chitosan-DNA nanoparticles with poly(propyl acrylic acid) enhances gene expression
T. Kiang (2004)
10.1007/BF02976620
Recent progress in drug delivery systems for anticancer agents
C. Kim (2002)
10.1007/BF02897257
Hepatic tissue distribution of doxorubicin-loaded nanoparticles after i.v. administration in reticulosarcoma M 5076 metastasis-bearing mice
N. Chiannilkulchai (2008)
10.1016/S1359-6446(02)02444-3
Therapeutic synthetic polymers: a game of Russian roulette?
A. C. Hunter (2002)
10.1016/J.JCONREL.2004.11.016
Physically bonded nanoparticle networks: a novel drug delivery system.
X. Xia (2005)
10.1046/J.0014-2956.2001.02671.X
Different mechanisms for cellular internalization of the HIV-1 Tat-derived cell penetrating peptide and recombinant proteins fused to Tat.
M. Silhol (2002)
10.1016/S0168-3659(01)00495-3
Design of novel bioconjugates for targeted drug delivery.
Zheng-Rong Lu (2002)
10.1016/J.JCONREL.2004.07.032
Altered chemical and biological activities of all-trans retinoic acid incorporated in solid lipid nanoparticle powders.
Soo-Jeong Lim (2004)
10.1089/SCT.1989.5.1
Doxorubicin-loaded nanoparticles: increased efficiency in murine hepatic metastases.
N. Chiannilkulchai (1989)
10.1021/JA0296935
Multifunctional gold nanoparticle-peptide complexes for nuclear targeting.
A. Tkachenko (2003)
10.1016/J.BIOMATERIALS.2003.09.055
Methoxy poly(ethylene glycol)-poly(lactide) (MPEG-PLA) nanoparticles for controlled delivery of anticancer drugs.
Yuancai Dong (2004)
10.1016/J.CANLET.2004.03.038
Magnetite nanoparticle-loaded anti-HER2 immunoliposomes for combination of antibody therapy with hyperthermia.
A. Ito (2004)
10.1016/J.JCONREL.2004.11.018
Release kinetics of hydrophobic and hydrophilic model drugs from pluronic F127/poly(lactic acid) nanoparticles.
X. Xiong (2005)
10.1021/LA047367S
Amphiphilic hydrogel nanoparticles. Preparation, characterization, and preliminary assessment as new colloidal drug carriers.
Dimitris Missirlis (2005)
10.1016/S0168-3659(01)00530-2
PLGA-mPEG nanoparticles of cisplatin: in vitro nanoparticle degradation, in vitro drug release and in vivo drug residence in blood properties.
K. Avgoustakis (2002)
10.1016/S0168-3659(01)00554-5
Enhanced tumor cell selectivity of adriamycin-monoclonal antibody conjugate via a poly(ethylene glycol)-based cleavable linker.
T. Suzawa (2002)
10.1016/J.BIOMATERIALS.2004.06.004
Synthesis and drug release behavior of poly (trimethylene carbonate)-poly (ethylene glycol)-poly (trimethylene carbonate) nanoparticles.
Y. Zhang (2005)
10.1016/S0040-4039(00)00619-5
A new polymer-bound N-hydroxysuccinimidyl active ester linker
H. Shao (2000)
10.1023/A:1022219003551
Dynamics of Endocytosis and Exocytosis of Poly(D,L-Lactide-co-Glycolide) Nanoparticles in Vascular Smooth Muscle Cells
J. Panyam (2004)
10.1016/S0142-9612(02)00440-4
Intracellular uptake of anionic superparamagnetic nanoparticles as a function of their surface coating.
C. Wilhelm (2003)
10.1007/BF02940287
Tissue distribution of doxorubicin associated with polyisohexylcyanoacrylate nanoparticles
C. Verdun (2008)
10.1016/J.EJPS.2004.04.003
Cystatin incorporated in poly(lactide-co-glycolide) nanoparticles: development and fundamental studies on preservation of its activity.
Mateja Cegnar (2004)
10.1248/CPB.49.1444
In vitro and in vivo study of two types of long-circulating solid lipid nanoparticles containing paclitaxel.
D. Chen (2001)
10.1016/J.ADDR.2003.10.047
Bottom-up design of biomimetic assemblies.
R. Tu (2004)
10.1016/J.EJPB.2004.02.016
Polysaccharide-decorated nanoparticles.
C. Lemarchand (2004)
10.1562/0031-8655(2001)073<0388:EODPFU>2.0.CO;2
Evaluation of Different Photosensitizers for Use in Photochemical Gene Transfection¶
L. Prasmickaite (2001)
10.1016/S0022-2836(02)00031-1
A biological transporter for the delivery of peptide nucleic acids (PNAs) to the nuclear compartment of living cells.
K. Braun (2002)
10.1021/NL050074E
Surface plasmon resonance scattering and absorption of anti-EGFR antibody conjugated gold nanoparticles in cancer diagnostics: applications in oral cancer.
I. El-Sayed (2005)
10.1016/J.BIOMATERIALS.2004.07.050
Effects of particle size and surface coating on cellular uptake of polymeric nanoparticles for oral delivery of anticancer drugs.
K. Y. Win (2005)
10.1016/J.JHEP.2004.12.035
Increase of doxorubicin sensitivity by doxorubicin-loading into nanoparticles for hepatocellular carcinoma cells in vitro and in vivo.
L. Barraud (2005)



This paper is referenced by
10.1080/17425247.2020.1779218
Novel drug delivery systems of β2 adrenoreceptor agonists to suppress SNCA gene expression and mitochondrial oxidative stress in Parkinson’s disease management
Piyong Sola (2020)
10.2478/v10077-011-0005-9
NANOTECHNOLOGIES IN DEVELOPMENT OF STRUCTURAL MATERIALS AND BIOMATERIALS
A. Zieliński (2011)
10.1007/978-3-662-43787-2
The Blood Brain Barrier (BBB)
G. Fricker (2014)
10.1007/978-3-540-74855-7_1
Mechanochemistry and Nanoscience
P. Baláž (2008)
10.1016/j.drudis.2008.09.005
The targeted delivery of cancer drugs across the blood-brain barrier: chemical modifications of drugs or drug-nanoparticles?
L. Juillerat-Jeanneret (2008)
10.1016/j.semcancer.2020.01.011
Targeting cancer cells with nanotherapeutics and nanodiagnostics: Current status and future perspectives.
Eunus S Ali (2020)
10.3109/17435390.2013.826743
Biological impact assessment of nanomaterial used in nanomedicine. Introduction to the NanoTEST project
L. Juillerat-Jeanneret (2015)
10.1155/2015/320941
Blood Brain Barrier: A Challenge for Effectual Therapy of Brain Tumors
Arijit Bhowmik (2015)
10.1007/7355_2013_22
Nanoparticles as Blood-Brain Barrier Permeable CNS Targeted Drug Delivery Systems
A. Grabrucker (2013)
10.1016/B978-0-323-46143-6.00027-0
Drug delivery: advancements and challenges
Narinder Singh (2017)
10.3390/toxins2061568
Arsenic in Cancer Treatment: Challenges for Application of Realgar Nanoparticles (A Minireview)
P. BalᎠ(2010)
10.1016/J.JDDST.2020.102098
Current approaches and prospective drug targeting to brain
Rizwana Khatoon (2020)
10.1016/B978-0-323-46152-8.00021-4
Nanocarriers for Photosensitizers for Use in Antimicrobial Photodynamic Therapy
J. Sobczyński (2017)
Semantic Scholar Logo Some data provided by SemanticScholar